Failure to have fully recovered (that is, less than or equal to [<=] Grade 1 toxicity) from the reversible effects of prior chemotherapy.
Major surgery within 14 days before enrollment.
Radiotherapy within 14 days before enrollment (if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib.)
Central nervous system involvement.
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
Has greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period.
PD on first-line therapy.
Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial. Non-interventional trials (that is, observational trials) are permitted at any time point.

NCT03173092_exc_T1
Negation
Failure
NCT03173092_exc_T2
Condition
fully recovered
NCT03173092_exc_T3
Value
less than or equal to [<=] Grade 1
NCT03173092_exc_T4
Measurement
toxicity
NCT03173092_exc_T5
Procedure
chemotherapy
NCT03173092_exc_T6
Scope
Failure to have fully recovered
NCT03173092_exc_T7
Scope
less than or equal to [<=] Grade 1 toxicity
NCT03173092_exc_T8
Procedure
Major surgery
NCT03173092_exc_T9
Temporal
within 14 days before enrollment
NCT03173092_exc_T10
Procedure
Radiotherapy
NCT03173092_exc_T11
Temporal
within 14 days before enrollment
NCT03173092_exc_T12
Observation
involved field is small
NCT03173092_exc_T13
Temporal
7 days
NCT03173092_exc_T14
Scope
thin 14 days before enrollment ( volved field is small, 7 days w
NCT03173092_exc_T15
Condition
Central nervous system involvement
NCT03173092_exc_T16
Condition
Infection
NCT03173092_exc_T17
Procedure
systemic antibiotic therapy
NCT03173092_exc_T18
Qualifier
other
NCT03173092_exc_T19
Qualifier
serious
NCT03173092_exc_T20
Condition
infection
NCT03173092_exc_T21
Temporal
within 14 days before study enrollment
NCT03173092_exc_T22
Condition
cardiovascular conditions
NCT03173092_exc_T23
Qualifier
uncontrolled
NCT03173092_exc_T24
Condition
hypertension
NCT03173092_exc_T25
Qualifier
uncontrolled
NCT03173092_exc_T26
Condition
cardiac arrhythmias
NCT03173092_exc_T27
Qualifier
symptomatic
NCT03173092_exc_T28
Condition
congestive heart failure
NCT03173092_exc_T29
Condition
unstable angina
NCT03173092_exc_T30
Condition
myocardial infarction
NCT03173092_exc_T31
Temporal
within the past 6 months
NCT03173092_exc_T32
Qualifier
uncontrolled
NCT03173092_exc_T33
Temporal
current
NCT03173092_exc_T34
Scope
uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
NCT03173092_exc_T35
Scope
current uncontrolled cardiovascular conditions
NCT03173092_exc_T36
Procedure
Systemic treatment
NCT03173092_exc_T37
Temporal
within 14 days before the first dose of ixazomib
NCT03173092_exc_T38
Reference_point
the first dose of ixazomib
NCT03173092_exc_T39
Drug
ixazomib
NCT03173092_exc_T40
Drug
strong cytochrome P450 3A (CYP3A) inducers
NCT03173092_exc_T41
Drug
rifampin
NCT03173092_exc_T42
Drug
rifapentine
NCT03173092_exc_T43
Drug
rifabutin
NCT03173092_exc_T44
Drug
carbamazepine
NCT03173092_exc_T45
Drug
phenytoin
NCT03173092_exc_T46
Drug
phenobarbital
NCT03173092_exc_T47
Scope
rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital
NCT03173092_exc_T48
Drug
Ginkgo biloba
NCT03173092_exc_T49
Drug
St. John's wort
NCT03173092_exc_T50
Scope
strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
NCT03173092_exc_T51
Qualifier
active
NCT03173092_exc_T52
Temporal
Ongoing
NCT03173092_exc_T53
Condition
systemic infection
NCT03173092_exc_T54
Qualifier
active
NCT03173092_exc_T55
Condition
is B or C v nfection, or kn
NCT03173092_exc_T56
Condition
C virus infection
NCT03173092_exc_T57
Scope
hepatitis B or C virus infection
NCT03173092_exc_T58
Scope
Ongoing or active
NCT03173092_exc_T59
Measurement
human immunodeficiency virus
NCT03173092_exc_T60
Value
positive
NCT03173092_exc_T61
Condition
malignancy
NCT03173092_exc_T62
Temporal
within 2 years before study enrollment
NCT03173092_exc_T63
Temporal
previously
NCT03173092_exc_T64
Qualifier
another
NCT03173092_exc_T65
Condition
malignancy
NCT03173092_exc_T66
Condition
residual disease
NCT03173092_exc_T67
Mood
any evidence of
NCT03173092_exc_T68
Condition
non-melanoma skin cancer
NCT03173092_exc_T69
Condition
carcinoma in situ
NCT03173092_exc_T70
Qualifier
any type
NCT03173092_exc_T71
Negation
not excluded
NCT03173092_exc_T72
Procedure
complete resection
NCT03173092_exc_T73
Scope
non-melanoma skin cancer or carcinoma in situ of any type
NCT03173092_exc_T74
Qualifier
greater than or equal to (>=) Grade 2
NCT03173092_exc_T75
Condition
peripheral neuropathy
NCT03173092_exc_T76
Qualifier
Grade 1
NCT03173092_exc_T77
Condition
pain
NCT03173092_exc_T78
Scope
Grade 1 with pain
NCT03173092_exc_T79
Scope
greater than or equal to (>=) Grade 2 peripheral neuropathy
NCT03173092_exc_T80
Drug
PD
NCT03173092_exc_T81
Qualifier
first-line therapy
NCT03173092_exc_T83
Temporal
within 30 days of the start of this trial
NCT03173092_exc_T84
Temporal
throughout the duration of this trial
NCT03173092_exc_T85
Reference_point
the start of this trial
NCT03173092_exc_T86
Reference_point
the duration of this trial
NCT03173092_exc_T87
Scope
within 30 days of the start of this trial and throughout the duration of this trial